Paradromics Inc. became the latest company developing a brain-computer interface (BCI) system to implant its technology, Connexus, into a human. The device was safely implanted, it recorded electrical brain signals and was removed intact in less than 20 minutes. Paradromics hopes to begin clinical trials later this year.
The U.S. FDA gave Sarepta Therapeutics Inc.’s rAAVrh74 viral vector, used in an investigational gene therapy for the treatment of limb-girdle muscular dystrophy, a step up, making it one of the first platforms to receive the agency’s platform technology designation.
Sensorium Therapeutics Inc. has identified mesembrine analogues acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of neurological disorders.
Astrocytes are crucial for brain homeostasis and synaptic activity under healthy conditions, and are activated during neuroinflammation, neural damage and neurodegeneration, such as in Alzheimer's disease (AD).
Privately held Beckley Psytech Ltd. is to be taken over by Atai Life Sciences in an all-share deal that values the U.K. psychedelic drug specialist at $370 million. After making a $50 million investment in January 2024, Berlin-based Atai already owns 36% of Beckley. It will now issue 105 million new shares to its fellow Beckley investors, giving them 34% ownership of the merged company.
Astellas Engineered Small Molecules US Inc. has identified poly(ADP-ribose) polymerase (PARP) inhibitors, particularly PARP-1 (ARTD1), reported to be useful for the treatment of neuronal injury.
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction, neuronal loss and the accumulation of amyloid plaques and neurofibrillary tangles, ultimately leading to cognitive decline. Despite significant research efforts, no existing treatment has proven effective enough to stop or reverse the progression of the disease.
Intra-Cellular Therapies Inc. has identified phosphodiesterase PDE1 inhibitors reported to be useful for the treatment of cancer, Parkinson’s disease, cognitive disorders, narcolepsy, female sexual dysfunction, glaucoma, psychosis and traumatic brain injury, among other disorders.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra, leading to clinical symptoms such as tremors, rigidity, bradykinesia and postural instability.
RSS
